Terms: = Germ cell tumor AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Prognosis
19 results:
1. [WHO Histological Classification of Pituitary tumors].
Nishioka H
No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
[TBL] [Abstract] [Full Text] [Related]
2. [Clinicopathological Features of Primary Small cell Neuroendocrine Carcinoma of the Bladder].
Gu YM; Liang XL; Zhang YG; Zhao HY; Jin ML; Li X; Lu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):429-435. PubMed ID: 37407530
[TBL] [Abstract] [Full Text] [Related]
3. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
[TBL] [Abstract] [Full Text] [Related]
4. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract] [Full Text] [Related]
5. LncRNA SNHG1 regulates neuroblastoma cell fate via interactions with HDAC1/2.
Hsu CL; Yin CF; Chang YW; Fan YC; Lin SH; Wu YC; Huang HC; Juan HF
Cell Death Dis; 2022 Sep; 13(9):809. PubMed ID: 36130928
[TBL] [Abstract] [Full Text] [Related]
6. Urinary Large cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases.
Wang G; Yuan R; Zhou C; Guo C; Villamil C; Hayes M; Eigl BJ; Black P
Am J Surg Pathol; 2021 Oct; 45(10):1399-1408. PubMed ID: 34074810
[TBL] [Abstract] [Full Text] [Related]
7. The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumours.
Wruck W; Bremmer F; Kotthoff M; Fichtner A; Skowron MA; Schönberger S; Calaminus G; Vokuhl C; Pfister D; Heidenreich A; Albers P; Adjaye J; Nettersheim D
J Cell Mol Med; 2021 Feb; 25(3):1394-1405. PubMed ID: 33448076
[TBL] [Abstract] [Full Text] [Related]
8. Epigenetic deregulation of gata3 in neuroblastoma is associated with increased gata3 protein expression and with poor outcomes.
Almutairi B; Charlet J; Dallosso AR; Szemes M; Etchevers HC; Malik KTA; Brown KW
Sci Rep; 2019 Dec; 9(1):18934. PubMed ID: 31831790
[TBL] [Abstract] [Full Text] [Related]
9. [Neuroendocrine differentiation in breast cancer].
Kreipe HH
Pathologe; 2019 Dec; 40(Suppl 3):325-330. PubMed ID: 31781853
[TBL] [Abstract] [Full Text] [Related]
10. Case of low-grade neuroendocrine carcinoma of the skin presenting metastases to lymph nodes and peritoneum.
Okabayashi A; Nakagawa K; Shimizu N; Tohda-Kinoshita R; Goto K
J Dermatol; 2019 Aug; 46(8):720-723. PubMed ID: 31206216
[TBL] [Abstract] [Full Text] [Related]
11. CD276 and the gene signature composed of gata3 and LGALS3 enable prognosis prediction of glioblastoma multiforme.
Takashima Y; Kawaguchi A; Hayano A; Yamanaka R
PLoS One; 2019; 14(5):e0216825. PubMed ID: 31075138
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Lavigne M; Menet E; Tille JC; Lae M; Fuhrmann L; Bonneau C; Deniziaut G; Melaabi S; Ng CCK; Marchiò C; Rouzier R; Bièche I; Vincent-Salomon A
Mod Pathol; 2018 Jan; 31(1):68-82. PubMed ID: 28884749
[TBL] [Abstract] [Full Text] [Related]
13. [Diagnostic value of immunohistochemistry and FISH for chromosome 12p in type Ⅱ testicular germ cell tumors].
Shen Q; Rao Q; Yu B; Xia QY; Bao W; Lu ZF; Shi QL; Zhou XJ
Zhonghua Nan Ke Xue; 2016 Aug; 22(8):692-697. PubMed ID: 29019224
[TBL] [Abstract] [Full Text] [Related]
14. gata3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma.
So JS; Epstein JI
Mod Pathol; 2013 Oct; 26(10):1365-70. PubMed ID: 23599157
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and gata3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract] [Full Text] [Related]
16. [Interstitial boost and altered fractionation as novel approaches to dose escalation in the radiotherapy of glioblastoma multiforme].
Mangel L; Julow J; Major T; Hável J; Lövey J; Viola A; Somogyi A; Németh G
Orv Hetil; 2003 Feb; 144(5):223-9. PubMed ID: 12647551
[TBL] [Abstract] [Full Text] [Related]
17. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
Uchino S; Noguchi S; Yamashita H; Sato M; Adachi M; Yamashita H; Watanabe S; Ohshima A; Mitsuyama S; Iwashita T; Takahashi M
Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
[TBL] [Abstract] [Full Text] [Related]
18. High-dose-rate brachytherapy for poor-prognosis, high-grade glioma: (phase II) preliminary results.
Micheletti E; La Face B; Feroldi P; Galelli M; Buttolo L; Stefini R; Giunta F
Tumori; 1996; 82(4):339-44. PubMed ID: 8890967
[TBL] [Abstract] [Full Text] [Related]
19. High-dose interstitial brachytherapy for glioblastoma multiforme.
Micheletti E; Baroncelli G; La Face B; Feroldi P; Galelli M; Giunta F
Tumori; 1994 Feb; 80(1):44-9. PubMed ID: 8191598
[TBL] [Abstract] [Full Text] [Related]
